3.76
price up icon1.62%   0.06
after-market After Hours: 3.83 0.07 +1.86%
loading
Marker Therapeutics Inc stock is traded at $3.76, with a volume of 85,606. It is up +1.62% in the last 24 hours and up +34.29% over the past month. Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
See More
Previous Close:
$3.70
Open:
$3.84
24h Volume:
85,606
Relative Volume:
2.42
Market Cap:
$33.55M
Revenue:
-
Net Income/Loss:
$-8.24M
P/E Ratio:
-2.4103
EPS:
-1.56
Net Cash Flow:
$-16.44M
1W Performance:
-7.62%
1M Performance:
+34.29%
6M Performance:
-8.52%
1Y Performance:
+23.28%
1-Day Range:
Value
$3.6271
$4.245
1-Week Range:
Value
$3.52
$4.30
52-Week Range:
Value
$2.4377
$6.1568

Marker Therapeutics Inc Stock (MRKR) Company Profile

Name
Name
Marker Therapeutics Inc
Name
Phone
(713) 400-6400
Name
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Name
Employee
8
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MRKR's Discussions on Twitter

Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-25-21 Initiated Piper Sandler Overweight
Mar-19-21 Initiated Cantor Fitzgerald Overweight
May-12-20 Downgrade Piper Sandler Overweight → Neutral
May-30-19 Initiated ROTH Capital Buy
Mar-01-19 Initiated Janney Buy
Dec-03-18 Upgrade Piper Jaffray Neutral → Overweight
View All

Marker Therapeutics Inc Stock (MRKR) Latest News

pulisher
Oct 23, 2024

US Penny Stocks To Consider In October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts

Oct 21, 2024
pulisher
Oct 16, 2024

Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance

Oct 16, 2024
pulisher
Oct 01, 2024

PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK

Oct 01, 2024
pulisher
Sep 26, 2024

AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance

Sep 26, 2024
pulisher
Sep 23, 2024

Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines

Sep 23, 2024
pulisher
Sep 23, 2024

On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS

Sep 23, 2024
pulisher
Sep 23, 2024

ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire

Sep 23, 2024
pulisher
Sep 23, 2024

ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Sep 23, 2024
pulisher
Sep 21, 2024

Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN

Sep 21, 2024
pulisher
Sep 20, 2024

Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 20, 2024
pulisher
Sep 20, 2024

Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech

Sep 20, 2024
pulisher
Sep 20, 2024

Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily

Sep 20, 2024
pulisher
Sep 20, 2024

Hematopoietic stem cell transplantation (HSCT) Market to See - openPR

Sep 20, 2024
pulisher
Sep 20, 2024

Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool

Sep 20, 2024
pulisher
Sep 20, 2024

Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 19, 2024
pulisher
Sep 18, 2024

Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail

Sep 18, 2024
pulisher
Sep 17, 2024

Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show

Sep 17, 2024
pulisher
Sep 17, 2024

Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 17, 2024
pulisher
Sep 14, 2024

Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World

Sep 14, 2024
pulisher
Sep 14, 2024

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World

Sep 14, 2024
pulisher
Sep 14, 2024

United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Sep 12, 2024
pulisher
Sep 05, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire

Sep 05, 2024
pulisher
Aug 30, 2024

Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World

Aug 30, 2024
pulisher
Aug 28, 2024

Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance

Aug 28, 2024
pulisher
Aug 27, 2024

Raymond James & Associates Has $10.59 Million Stock Holdings in InvescoBulletShares2033 Corporate Bond ETF (NASDAQ:BSCX) - Defense World

Aug 27, 2024
pulisher
Aug 21, 2024

MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

Will APOLLO Study Of MT-601 In Lymphoma Make A Mark? - RTTNews

Aug 19, 2024
pulisher
Aug 14, 2024

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Aug 14, 2024
pulisher
Aug 12, 2024

Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN

Aug 12, 2024
pulisher
Aug 12, 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in - GlobeNewswire

Aug 12, 2024
pulisher
Aug 12, 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma - StockTitan

Aug 12, 2024
pulisher
Aug 02, 2024

Breast Tissue Markers Market Size to be Worth USD 5.8 billion by 2034, Growing at CAGR of 8.3% | Exclusive Report by Transparency Market Research, Inc. - Yahoo Finance

Aug 02, 2024
pulisher
Aug 01, 2024

NightHawk Changes Name To Scorpius Holdings - Contract Pharma

Aug 01, 2024
pulisher
Jul 29, 2024

IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jul 29, 2024
pulisher
Jul 28, 2024

(MRKR) Investment Report - Stock Traders Daily

Jul 28, 2024
pulisher
Jul 27, 2024

Soligenix (NASDAQ:SNGX) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Contrast - Defense World

Jul 27, 2024
pulisher
Jul 27, 2024

Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $40.60 - Defense World

Jul 27, 2024

Marker Therapeutics Inc Stock (MRKR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.89
price up icon 2.45%
$80.95
price up icon 4.75%
$397.49
price up icon 3.85%
$51.81
price down icon 2.78%
$202.73
price down icon 2.55%
$106.64
price down icon 3.90%
Cap:     |  Volume (24h):